Right Therapy, Right Time: Guiding MS Treatment Amid Advancing Options

EP: 1.Understanding PIRA and Its Clinical Significance in MS

EP: 2.Measuring What Matters: Evidence and End Points That Define Disability in MS

EP: 3.Closing the Gaps: Therapeutic Performance and the Promise of Innovation

EP: 4.Digging Deeper: Mechanisms of Progression and the Case for a Dual Therapeutic Approach

EP: 5.Aligning Evidence With Access: Disability Outcomes, Data, and Payer Decision-Making

EP: 6.Bridging the Gaps: BTK Inhibitors and the Future of MS Care

EP: 7.Redefining Value: What Payers Want From Comprehensive MS Treatments

EP: 8.Short-Term Wins vs Long-Term Gains: Rethinking MS Treatment Value

EP: 9.Evaluating the Future of MS Therapies: Balancing Early Data With Delayed Outcomes

EP: 10.Beyond Relapses: BTK Inhibitor Coverage Strategies for PIRA in MS

EP: 11.The Value of Functional Outcomes and Elevating Patient Voices in MS Assessments

EP: 12.Modeling the Cost of Progression: Capturing the True Burden of MS

Now Viewing

EP: 13.Right Therapy, Right Time: Guiding MS Treatment Amid Advancing Options

Video content above is prompted by the following:

The Project ECHO (Extension for Community Healthcare Outcomes) model addresses the challenge of multiple sclerosis (MS) expertise concentration in academic centers by training community neurologists through telehealth-based education programs. This collaborative approach allows general neurologists to manage MS patients with specialist support, reducing patient travel burden while maintaining quality care. The program creates consistency in treatment approaches across different practice settings, which is particularly important as complex therapies like Bruton tyrosine kinase (BTK) inhibitors enter the market requiring sophisticated patient selection and monitoring.

Colorado’s health care landscape exemplifies the challenges faced by many states with significant rural populations, where 5 out of 68 counties contain most tertiary care resources. The harsh winter conditions and long travel distances make centralized MS care impractical for many patients. Project ECHO and similar programs help democratize MS expertise by providing ongoing education and support to community providers, ensuring that geographic location doesn’t determine access to optimal care. This approach is particularly crucial for implementing newer therapies like BTK inhibitors that require specialized knowledge.

The collaboration between academic medical centers and community providers creates a sustainable model for MS care delivery that benefits all stakeholders. Academic centers fulfill their mission of education and innovation while extending their reach, community providers gain confidence in managing complex conditions, and patients receive expert-level care closer to home. This partnership model is essential for implementing emerging treatments like BTK inhibitors, where community providers need support in patient selection, monitoring, and management of potential adverse effects.